Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: Secondary analysis of trial data

BMJ (Online)

Volumn 338, Issue 7710, 2009, Pages 1553-

  Bell, Katy J L ^a   Hayen, Andrew ^a   Macaskill, Petra ^a   Irwig, Les ^a   Craig, Jonathan C ^a   Ensrud, Kristine ^b   Bauer, Douglas C ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; PLACEBO; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MONITORING; FEMALE; HIP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; POSTMENOPAUSE; PRIORITY JOURNAL; SPINE; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, SPONTANEOUS; HIP JOINT; HUMANS; OSTEOPOROSIS; POSTMENOPAUSE; UNNECESSARY PROCEDURES;

EID: 67650045590     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b2266     Document Type: Article

References (28)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteopor Int 2006;17:1726-33.
2. AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64.
3. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington DC: NOF, 2008. (Available from: www.nof.org)
4. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
5. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 suppl):S1-34.
6. Writing Group of the Bone and Tooth Society of Great Britain and Royal College of Physicians. Osteoporosis. Clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. 2000. www.rcplondon.ac.uk/pubs/wp/wp-osteo-update.htm.
7. National Osteoporosis Guidelines Group (NOGG). Osteoporosis clinical guideline for prevention and treatment. 2008 (www. iofbonehealth.org/download/ osteofound/filemanager/ policy-advocacy/EU-consultation-panel-meetings/overview- uknational-osteoporosis-guidelines-group-08.pdf)
8. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteopor Int 2005;16:229-38.
9. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6.
10. Cummings S, Karpf D, Harris F, Genant H, Ensrud K, LaCroix A, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9.
11. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92.
12. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal B, Irwig L. Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. J Clin Epidemiol 2009;62:650-9.
13. Bell KJL, Irwig L, Craig JC, Macaskill P. Use of randomised trials to decide when to monitor response to new treatment. BMJ 2008;336:361-5.
14. Black DM, Nevitt MC, Cauley J, Karpf D, Cummings SR. Design of the fracture intervention trial. Osteopor Int 1993;3(suppl 3):S29-39.
15. Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M, et al. Randomised trial of effect of alendronate on risk of fracture inwomen with existing vertebral fractures. Lancet 1996;348:1535-41.
16. Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82.
17. Goldstein H, Browne W, Rabash J. Multilevel modelling of medical data. Stat Med 2002;21:3291-315
18. Singer J, Willet J. Doing data analysis with the multilevel model for change. In: Applied longitudinal data analysis. New York: Oxford University Press, 2003:75-137.
19. Leslie WD, Lix LM, Tsang JF, Caetano PA. Single-site vsmultisite bone density measurement for fracture prediction. Arch Int Med 2007;167:1641-7.
20. Lu Y, Genant HK, Shepherd J, Zhao S, Mathur A, Fuerst TP, et al. Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 2001;16:901-10.
21. Bland JM, Altman DG. Measurement error. BMJ 1996;313:744.
22. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient compliance. Hypertension 1980;2:757-64.
23. Cummings S, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 2000;283:1318-21.
24. Haynes RB, Sackett DL, Taylor DW. How to detect and manage low patient compliance in chronic illness. Geriatrics 1980;35:91-7.
25. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of bisphosphonates: current status. Clin Cancer Res 2006;12(20 suppl):6222-30s.
26. Pavlic M, Brand B, Cummings S. Estimating probability of nonresponse to treatment using mixture distributions. Stat Med 2001;20:1739-53.
27. Chapurlat RD, Palermo L, Ramsay P, Cummings S. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 2005;16:842-8.
28. Morton V, Torgenson D. Regression to the mean: treatment effect without the intervention. J Eval Clin Pract 2004;11:59.